Outcome of Classical Hodgkin’s Lymphoma Treatment Based on High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery

Aim. To estimate the long-term outcome of the programmed treatment of classical Hodgkin’s lymphoma (cHL) including high-dose chemotherapy (HDCT) and autologous hematopoietic stem cell transplantation (auto-HSCT) as well as the effect of various factors on the achieved results in a single-center study.

Materials & Methods. In the A.A. Maksimov Clinical Center of Hematology and Cellular Therapy of the NI Pirogov Russian National Medical Center of Surgery 260 cHL patients received HDCT combined with auto-HSCT within the period from December 2006 to March 2017. The median age was 29 years (range 17–62). The study included 40 % men (n = 104), and 60 % women (n = 156). The median pretransplantation chemotherapy line was 3 (range 2–9). At this stage, prior to auto-HSCT, complete remission (CR) rate was 26.5 %, partial remission (PR) rate was 52.3 %, disease stabilisation rate was 13.5 %. HDCT with auto-HSCT was applied beyond progression as a salvage therapy in 7.7 % of patients. In 79.6 % of patients the standard BEAM and CBV conditioning regimens were used.

Results. After HDCT combined with auto-HSCT overall 5-year survival (OS) of 260 cHL patients was 74 %, and 5-year progression-free survival (PFS) was 48 %, which corresponds to the results of some international studies. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during the first CR or PR (85 %) vs the second and subsequent CR and PR (71 %). Neither gender (p = 0.4) nor ECOG status (p = 0.2) effects on OS and PFS were revealed. 5-year OS rates were significantly higher after HDCT and auto-HSCT performed during CR or PR (82 %) vs disease stabilisation and progression (54 %) as well as upon achieving CR (93 %) vs PR (77 %).

Conclusion. In cHL tumor sensitivity to chemotherapy is the essential indication for HDCT combined with auto-HSCT. The optimal time for HDCT and auto-HSCT in cHL is the first CR/PR, and the best treatment outcome is achieved in patients with complete response prior to HDCT and auto-HSCT.

• Nikita Evgen’evich Mochkin NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• V.O. Sarzhevskii NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• Yu.N. Dubinina NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• E.G. Smirnova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• D.A. Fedorenko NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• A.E. Bannikova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• D.S. Kolesnikova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• V.S. Bogatyrev NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• N.M. Faddeev NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
• V.Ya. Mel’nichenko NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203

1. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М.: Буки Веди, 2016.[Poddubnaya IV, Savchenko VG, eds. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. (Russian clinical guidelines in diagnosis and treatment of lymphoproliferative disorders). Moscow: Buki Vedi Publ.; 2016. (In Russ)]
2. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–52. doi: 10.1016/S1470-2045(13)70341-3. DOI: https://doi.org/10.1016/S1470-2045(13)70341-3
3. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117(16):4208–17. doi: 10.1182/blood-2010-09-288373. DOI: https://doi.org/10.1182/blood-2010-09-288373
4. Thomas RK, Re D, Zander T, et al. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol. 2002;13(Suppl. 4):147–52. doi: 10.1093/annonc/mdf652. DOI: https://doi.org/10.1093/annonc/mdf652
5. Linch D, Winfield D, Goldstone A, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomized trial. Lancet. 1993;341(8852):1051–4. doi: 10.1016/0140-6736(93)92411-L. DOI: https://doi.org/10.1016/0140-6736(93)92411-L
6. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomized trial. Lancet. 2002;359(9323):2065–71. doi: 10.1016/S0140-6736(02)08938-9. DOI: https://doi.org/10.1016/S0140-6736(02)08938-9
7. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002;20(1):221–30. doi: 10.1200/JCO.2002.20.1.221 DOI: https://doi.org/10.1200/JCO.20.1.221
8. Ljungman P, Bregni M, Brune M, et al. Allogenic and autologous transplantation for haematological disease, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219–34. doi: 10.1038/bmt.2009.141. DOI: https://doi.org/10.1038/bmt.2009.141
9. Perales M-A, Ceberio I, Armand Ph, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6):971–983. doi: 10.1016/j.bbmt.2015.02.022. DOI: https://doi.org/10.1016/j.bbmt.2015.02.022
10. Hoppe RT, Advani RH, Ai WZ, et al. NCCN Clinical Practice Guidelines in Oncology. Hodgkin Lymphoma. Version 1.2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf (accessed 05.03.2018).
11. Moscowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high-dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol. 2004;124(5):645–52. doi: 1111/j.1365-2141.2003.04828.x. DOI: https://doi.org/10.1111/j.1365-2141.2003.04828.x
12. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(7):1312–9. doi: 10.1093/annonc/mdn052. DOI: https://doi.org/10.1093/annonc/mdn052
13. Moskowitz CH, Nimer SD, Zelenets AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–23. doi: 10.1182/blood.V97.3.616. DOI: https://doi.org/10.1182/blood.V97.3.616
14. Phillips JK, Spearing RL, Davies JM, et al. VIM-D salvage chemotherapy in Hodgkin’s disease. Cancer Chemother Pharmacol. 1990;27(2):161–3. doi: 10.1007/bf00689103. DOI: https://doi.org/10.1007/BF00689103
15. The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. Ann Oncol 1995;6(2):167–72. DOI: https://doi.org/10.1093/oxfordjournals.annonc.a059112
16. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995;13(2):396–402. doi: 10.1200/JCO.1995.13.2.396. DOI: https://doi.org/10.1200/JCO.1995.13.2.396
17. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995;6(6):609–12. doi: 10.1093/oxfordjournals.annonc.a059252. DOI: https://doi.org/10.1093/oxfordjournals.annonc.a059252
18. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10(5):593–5. doi: 10.1023/a:1026454831340. DOI: https://doi.org/10.1023/A:1026454831340
19. Martin A, Femandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol. 2001;113(1):161–71. doi:1046/j.1365-2141.2001.02714.x. DOI: https://doi.org/10.1046/j.1365-2141.2001.02714.x
20. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628–35. doi: 10.1093/annonc/mdf221. DOI: https://doi.org/10.1093/annonc/mdf221
21. Abali H, Urun Y, Oksuzoglu B, et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest. 2008;26(4):401–6. doi: 10.1080/07357900701788098. DOI: https://doi.org/10.1080/07357900701788098
22. European Society for Blood and Marrow Transplantation Annual Report 2016. Available from: http://www.ebmt.org/sites/default/files/migration_legacy_files/document/Annual%20Report%202016_EBMT.pdf. (accessed 28.03.2018).
23. Passweg JR, Baldomero H, Bregni M, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant. 2013;48(9):1161–7. doi: 10.1038/bmt.2013.51. DOI: https://doi.org/10.1038/bmt.2013.51
24. Жуков Н.В., Усс А.Л., Миланович Н.Ф. и др. Оптимальные сроки проведения аутологичной трансплантации клеток предшественников гемопоэза при неблагоприятном течении лимфомы Ходжкина. Зарубежные рекомендации и отечественная практика. Онкогематология. 2014;2:37–44.[Zhukov NV, Uss AL, Milanovich NF, et al. The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin’s lymphoma. Foreign recommendations and Russian experience. Onkogematologiya. 2014;2:37–44. (In Russ)]
25. Мочкин Н.Е., Саржевский В.О., Дубинина Ю.Н. и др. Высокодозная химиотерапия с трансплантацией аутологичных кроветворных стволовых клеток при лимфоме Ходжкина. Десятилетний опыт ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России. Российский журнал детской гематологии и онкологии. 2017;4(2):85–90. doi: 10.17650/2311-1267-2017-4-2-85-90.[Mochkin NE, Sarzhevskii VO, Dubinina YuN, et al. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with Hodgkin’s lymphoma. 10-year experience of the NI Pirogov Russian National Medical Center of Surgery. Rossiiskii zhurnal detskoi gematologii i onkologii. 2017;4(2):85–90. doi: 17650/2311-1267-2017-4-2-85-90. (In Russ)] DOI: https://doi.org/10.17650/2311-1267-2017-4-2-85-90
26. Sasse S, Alram M, Muller H, et al. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.Leuk Lymphoma.2016;57(5):1067–73. doi: 10.3109/10428194.2015.1083561. DOI: https://doi.org/10.3109/10428194.2015.1083561
27. Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456–60. doi: 10.1200/JCO.2012.45.3308. DOI: https://doi.org/10.1200/JCO.2012.45.3308
28. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118(12):3419–25. doi: 10.1182/blood-2011-04-351924. DOI: https://doi.org/10.1182/blood-2011-04-351924
29. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patient: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20(6):451–8. doi: 10.1038/sj.bmt.1700913. DOI: https://doi.org/10.1038/sj.bmt.1700913
30. Jagannath S, Armitage JO, Dicke KA, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol. 1989;7(2):179–85. doi: 10.1200/jco.1989.7.2.179. DOI: https://doi.org/10.1200/JCO.1989.7.2.179
31. Provencio M, Sanchez A, Sanchez-Beato M. New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treat Rev. 2014;40(3):457–64. doi. 10.1016/j.ctrv.2013.09.005. DOI: https://doi.org/10.1016/j.ctrv.2013.09.005